Bacteremia caused by Clostridium sporogenes in an oncological patient.

Rev Esp Quimioter 2023;36(2): 217-219 217 itive. The samples were subcultured on aerobic or anaerobic blood agar (BD Columbia Agar with 5% Sheep Blood, Becton Dickinson, Franklin Lakes, NY). All media were incubated at 37 oC. The AnaeroGen Compact anaerobic system (Oxoid Ltd, Wide Road, Basingstoke, England) was used. Gram staining of the blood cultures revealed abundant Gram-positive bacilli; on 24 hours of incubation, abundant colonies of these microorganisms were observed in pure culture on anaerobic blood agar alone. MALDI-TOF MS version 9 (8468 msp) (Bruker Biotyper, Billerica, MA) was employed, identifying the strain as C. sporogenes (score 2.35). The strain was sent to the Centre of Genomic and Oncologic Research (GENYO, Granada, Spain) for 16S rRNA gene sequence analysis using a previously reported method [4]. A fragment of 1,329 bp was obtained, yielding 99.85% similarity with the C. botulinum type strain Mfbjulcb5 GenBank sequence (accession number CP027776.1) and C. sporogenes strain CDC 1632 GenBank sequence (accession number CP013243.1). Subsequently, the sequence was compared using another database (IeBIBI IV 16s Automated ProKaryotes Phylogeny) confirming the strain as C. sporogenes. The 16S sequence was submitted to the GenBank (accession number: OP431824).